AMO Pharma granted Fast Track designation by US FDA for potential treatment for congenital myotonic dystrophy

Source :: M2 EquityBites (EQB). May 30, 2017
Publication Year :: 2017
Abstract: M2 EQUITYBITES-May 30, 2017-AMO Pharma granted Fast Track designation by US FDA for potential treatment for congenital myotonic dystrophy (C)2017 M2 COMMUNICATIONS http://www.m2.com Privately owned biopharmaceutical company AMO Pharma Ltd [...]

Subjects :: United States. Food and Drug Administration
Myotonic dystrophy -- Drug therapy
Drug approval
Genetic disorders -- Drug therapy
Business

Tools